Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin or Zevalin-BEAM consolidation in transformed lymphoma
NL-OMON21852Phase 2Recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Jun 2010
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan and carmustine + cytarabine + etoposide + melphalan in non-Hodgkin lymphoma (t-NHL) (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: 2-year progression-free survival. Started Jun 2010; status: recruiting.
02
Drugs
ibritumomab tiuxetancarmustine + cytarabine + etoposide + melphalan
03
Conditions
non-Hodgkin lymphoma (t-NHL)
Beyond the preview
Go deeper on NL-OMON21852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21852.